Tags Posts tagged with "Recreational Marijuana"

Recreational Marijuana

0 6759

By Jason Spatafora @WolfofWeedSt

“I fear the Greeks, even those bearing gifts.”- Virgil

The DEA’s recent cannabis research expansion is a Harry Houdini inspired smoke show of misdirection all to set up the next trick; there I said it. While some view it as a positive first step, I tend to think it served a very deliberate function. Optically it played directly into expected vitriolic fallout from advocates, activists and media touts, all of which lined up to ignite their “DEA should reschedule cannabis” torches. In a “perfect world” scenario these people aren’t wrong, cannabis isn’t Heroin’s equal & 1+1=2, but just as fire cannot exist in a vacuum, neither can a rational cannabis debate. And while everyone on the side of reason is shouting in unison about rescheduling they failed to see that they might have just had their pockets picked. DEA’s policy statement that everyone seemed to ignore there are 33 words that have the potential to create the legal framework for the monopolization of Cannabis by means of an exclusionary application process.

Prologue – August 10th, 2016

Russ Baer, a staff coordinator for the Drug Enforcement Administration (DEA) media affairs wing gave a response to Steven Nelson of USNEWS.com via email. Nelson later shared a screen grab of the email via tweet. The statement made to him from this Drug Enforcement Administration staff coordinator read:

“Tomorrow morning (August 11th, 2016) the Drug Enforcement Administration will be making some important announcement regarding Marijuana related topics that will be published in the Federal Register. Because of your interest and/or prior engagement with the DEA on this subject, the DEA office of National Media Affairs is reaching out to you regarding these anticipated announcements.”

Over the next 24 hours social media was a blaze, with many people within the industry uncovering the fact that Rescheduling wouldn’t happen and that the DEA response would have to do with research. As expected, the incendiary scheduling of cannabis debate raged on into the following day.

August 11th, 2016

As expected, the Drug Enforcement Administration disappointed the advocates and activists of medical marijuana by not removing or rescheduling marijuana from its class 1 controlled substance status. Yet the DEA, in all of its benevolence, offered a consolation prize of sorts, by “deciding” to expand the study of Medical Marijuana for researchers, Universities & drug companies outside of the confines of a single federally legal facility. The facility, to refresh your memory is located at the University of Mississippi, (ranked 164th in Bio Sciences) and had up to this point been the sole research monopoly on legally grown marijuana, courtesy of the NIDA (National Institute on Drug Abuse).

DEA’s Misdirection Strategy

Over the next few days it seemed that every headline following the DEA’s deliberation was about the archaic rescheduling system & how cannabis is safer statistically than opiates that are schedule 2. Some media outlets went as far as to paint a “glass half full” picture. The LA Times for example did a piece titled “DEA ends its monopoly on marijuana growing for medical research.” The social reaction from cannabis enthusiasts, advocates and potrepreneurs from Main Street to Wall Street was as expected with everyone chiming in on social media to wag their fingers at the DEA. Representative Barbara Lee, a congresswoman from Oakland California stating via tweet “Politicians aren’t doctors or scientists. Marijuana research prohibitions are outdated, unscientific, & dangerous for those who need #MMJ.” As expected the rhetoric from the cannabis side was “The DEA is bad, the War on Drugs is a complete failure, Big Pharma is to blame,” so on and so forth.

IMG_8473

The people aren’t wrong on many of these points. The War in Drugs is a failure when considering addiction has been plateauing since its 1970 inception and US drug control spending is up 2000%, which to date stands at $1.5 trillion dollars. We can go on and on as to where that money went, what industries it created (prison industrial complex), the people it disproportionately targeted (minorities), but that’s a whole other article or book for that matter. Big Pharma however does have its trillion dollars hands in this story, but more on that later as I’ve digressed.

Not to go back and pick on the LA Times click-bate headline of “DEA ends its monopoly on marijuana growing for medical research,” but did it really end the monopoly? Let’s evaluate the idea. Yes, a monopoly is defined as “the exclusive possession or control of the supply or trade in a commodity or service.” The University of Mississippi was in fact in exclusive possession of the NIDA edict to legally grow marijuana and study it. On the surface the Monopoly has ended, but the reality is that we are just switching out the term Monopoly for an Oligarchy. Is an oligarchy any different than a monopoly in the sense that it’s just a smaller group carving out the biggest slices for themselves, eliminating competition by means of out maneuvering or outspending their opponent in an effort to influence policy such as this? Consider that the biggest lobby against the cannabis Industry is the pharmaceutical industry, yet they’re simultaneously studying cannabis for the purpose of synthesizing its many chemical compounds to create their high margin drugs.

Currently, their high margin bread and butter are the opioids for pain management such as OxyContin, Percocet and their generic versions of each. The drug companies are experts at isolating molecules from nature to create drugs that cost pennies to manufactures. In a zero sum game, cannabis is a direct threat to pharma companies, by snatching billions in profit and simultaneously causing billions in losses. Anti-cannabis lobbies would also be at risk as the pharmaceutical giants that feed them down on K Street would lose out on easy paydays. These anti-Marijuana lobbyists provide a micro look at the systemic problems within American politics illustrating how/why elected officials in Congress consistently vote against the interests of their collective constituency and bring forth carefully crafted bills or amendments like this one.

On the DEA’s policy statement and legal considerations section, under, legal applicable considerations it states.

“Second, as with any application submitted pursuant to section 823(a), in determining whether the proposed registrationwould be consistent with the public interest, among the factorsto be considered are whether the applicant has previous experience handling controlled substances in a lawful manner and whether the applicant has engaged in illegal activity involving controlled substances. In this context, illegal activity includes any activity in violation of the CSA (regardless of whether such activity is permissible under State law) as well as activity in violation of State or local law. While past illegal conduct involving controlled substances does not automatically disqualify an applicant, it may weigh heavily against granting the registration.”

Translation, grow marijuana even in a state where it’s legal and you are going to have a hard time becoming a manufacturer or researcher for the DEA’s new policy, thus excluding tier one cultivators in practice and likely creating a perpetual home for cannabis on the scheduling list. Prohibition’s end could very well be right around the corner, but the fear is in the form of legal medical marijuana at a Walgreens near you. I asked the DEA’s Russ Baer directly if the inserted language above in bold would be a non-starter for current cultivators wanting to become manufacturers as they are in clear Violation of CSA? In a written statement to Marijuana Stocks the DEA’s official response was:

“DEA is serious about facilitating marijuana research and that there is a lawful pathway for doing so. This DEA decision will facilitate increased research involving marijuana, within the framework of the law and U.S. treaty obligations, to enhance the drug’s supply available to researchers. The goal of this historic and monumental policy shift is to increase the amount and variety of marijuana available to researchers and make it easier for researchers to obtain marijuana as compared to current system under which marijuana must be obtained from NIDA. Growers must become registered with DEA, following the submission of an application, which DEA will evaluate in accordance with the CSA. Registered growers will need to comply with all CSA regulatory requirements, such as quotas, record keeping, order forms, and maintenance of control against diversion. Marijuana produced under this proposal may only be supplied to DEA-registered manufacturers and researchers, and only for purposes authorized by the CSA.

All potential new drugs, including drug products made from marijuana, are subject to the rigors of the drug approval process mandated by the Federal Food, Drug and Cosmetic Act (FDCA). This drug approval process requires that before a new drug is allowed to enter the U.S. market, it must be demonstrated through sound clinical trials to be both safe and effective for its intended uses,” stated Russ Baer of the Drug Enforcement Agency.

When asked if the inserted language also creates an unfair advantage for Pharma companies the response from the Drug Enforcement Administration circled back to the CSA (Controlled Substance Act) stating that the “DEA has adopted a new policy, consistent with the CSA and U.S. treaty obligations, under which additional entities may become registered with DEA to grow and distribute marijuana for research purposes. DEA will evaluate each application it receives to determine whether adding such applicant to the list of registered growers is necessary to provide an adequate and uninterrupted supply of marijuana to researchers in the U.S. In addition, applicants must demonstrate their ability to safely secure the drugs to prevent diversion, while abiding by the approved research protocol.”

The Controlled Substance Act

Everything points back to the Controlled Substance Act, a bill that was introduced into the Congress by Harley Staggers and took less than 6 weeks to get passed by the Senate and signed into law by President Richard M. Nixon. The signing of this document not only created the “War on Drugs,” but put an enforcement agency (DEA) in charge of Cannabis scheduling, circumventing the FDA in a move that creates an inter-agency firewall of sorts. The DEA’s position on why the FDA, who already regulates pharmaceutical drugs, isn’t in charge of marijuana rescheduling was point blank, “The Controlled Substances Act provides a mechanism for substances to be controlled (added to or transferred between schedules) or decontrolled (removed from control). The CSA provides roles for DEA and the FDA. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by DEA, HHS, or by petition from any interested party. Once initiated, the process involves a deliberate and collaborative interagency exchange.”

IMG_8472

In Laymen’s terms CSA effectively says “DEA you’re in charge of this, FDA you’re in charge of that.” Unfortunately, Marijuana will never be completely removed from the scheduling list unless there is a major political overhaul in every branch of government, if and only if elected officials stop letting lobbies pour honey in their ears and money into campaigns. The reality from my perspective is that the DEA is a scapegoat, the perfect Boogey Man, simply because their job is to follow orders. They are soldiers in a sense, adhering to the guidelines of the Controlled Substance Act (CSA), a legal document crafted by a congress, molded in the image of benefactors, used to fuel a fake war and create cottage industries.

The DEA knows marijuana is safer than Oxy and that’s not speculation that’s a direct quote. They don’t want to go after the mother transporting medication to her sick child because they’re suffering from seizures. They want the dangerous individuals like El Chapo or the pill mills slinging Oxy off the streets. They have no interest in going after all cultivators following state law to the letter. Are there exceptions, of course! Does it make these comments directly from them any less true? No.
DEA’s direct position on which drug is more dangerous from a consumption standpoint as it relates to Cannabis vs OxyContin? “There were more than 47,000 drug overdose deaths in 2014, or approximately 129 per day, more than half (61 percent) of which involved either a prescription opioid or heroin. Marijuana meets the statuary criteria of a Scheduled I controlled substance, and has been determined to have a high abuse potential with no currently accepted medical use. Schedule I includes some substances that are exceptionally dangerous (including heroin and LSD) and some that are less dangerous (including marijuana, which is less dangerous than some substances in other schedules).” When asked point blank, what’s more dangerous Oxy or Marijuana DEA says “Oxy.”

Robert Capecchi, Director of Federal Lobbying at the Marijuana Policy views medical marijuana legalization as a means to an opioid end as well as fiscal no brainer with far reaching benefits.

“Ending marijuana prohibition will allow licensed businesses to cultivate, distribute, and sell marijuana to adults. Unlike the criminal market, a legal and regulated market means products are pure, tested and labeled, sales are taxed, and business disputes are resolved in the courts, not with violence. Additionally, there is promising evidence to suggest that legal access to medical marijuana reduces the rates of opioid overdoses and the reliance on prescription pain killers.”

Foregone Conclusion?

Prohibition’s end could very well be right around the corner, but would we want it in the form of legal medical marijuana at a Walgreens near you? August 11th’s ruling was either one of many dominos in the quest for the monopolization of cannabis or just a pessimistic idea based off of history repeating itself. Regardless of which reality we are presently in, it doesn’t hurt to try and connect the dots, but if I can leave you with one last thing it’s the number 6630507. In case you’re wondering that’s the United States patent # they filed for cannabis in 2003 citing “multiple therapeutic uses.” I can only postulate why they did that….

Regards,

Jason Spatafora

Drug War

0 1494

Recreational pot shops might open in Nevada as early as July 1st under a deadline scheduled by the state’s top tax official recently. Regulators at the state Department of Taxation have been creating deadlines and regulations to govern recreational cannabis since voters in Nevada made it legal for adults 21 and older in November. Executive Director Deonne Contine told a panel of state legislators that she hopes to publicize a draft of those rules in March and begin accepting applications for temporary licenses to sell recreational marijuana in May, which would be far in advance of the state’s January 1, 2018 timeline.

Temporary licenses will only be open to medical pot shops in good standing with the state. Contine said she’s aiming to green-light those businesses to sell to the public by July 1st. Based on Contine’s unsure timeline, any entrepreneur could apply for a license to sell recreational cannabis in Nevada as soon as October 2018. Contine said Nevada’s laws will borrow heavily from the state’s medical cannabis rules and Colorado’s recreational pot laws. They will include a formula to set the wholesale price of pot, which will determine how much the state collects under a voter-approved 15% excise tax. The regulations also define how and who can transport cannabis.

While tax regulators work on those guidelines, Joe Pollock, an official who oversees the state’s medical cannabis industry, has increasing worry of how commercial pot will affect the drug landscape in Nevada. Pollock said of medical marijuana shops, “Basically the rurals don’t have dispensaries. If anything, I would be worried that the black market would move toward those rural counties because the recreational marijuana will not be available conveniently in those counties.” Of the almost 25,000 medical cannabis patients in Nevada, 482 of them are under the age of 21, according to Pollock, deputy administrator of the state’s Division of Public and Behavioral Health. Unless Nevada ensures medical cards and cheaper prices than recreational pot, Pollock said, those minors are some of the only patients with an incentive to continue using marijuana for medical purposes.

0 3256

California was already known as a major cannabis producer well before it legalized recreational marijuana in November. The state’s marijuana crop is not only the most profitable product in the nation’s biggest agricultural state, it is much farther ahead of the next most popular crop, according to the Orange County Register. California’s mild climate made Central Valley the breadbasket of the world at one time and provided the United States with fruits and vegetables that grew in very few other places. However, the biggest crop in California’s assorted bounty is currently marijuana.

The Orange County Register places the value of California’s marijuana crop above the top five best agricultural goods combined using data from the State Department of Food and Agriculture: Marijuana at $23.3 billion, Milk at $6.28 billion, Almonds at $5.33 billion, Grapes at $4.95 billion, Cattle/Calves at $3.39 billion, and Lettuce at $2.25 billion. The figure of $23.3 billion for the marijuana crop is almost three times what Arcview Market Research predicted that California’s legal market would be after legalization of recreational marijuana.

According to the California Protected Area Database, the total area of protected land in California is 49 million acres, which is a large amount for the most populous state in the country. This includes 1.3 million acres of state park land and more than 20 million acres of national forest.

California marijuana producers are clearly growing billions of dollars worth of pot in these areas that are not being accounted for by the state’s legal market. However, with most of the marijuana on the U.S. market coming from California, as Alternet pointed out, the phenomenon of growing on protected land won’t stop until people in states like New York and Florida can grow their own.

    0 3530

    Dr. Danial Schecter is the Co-Owner and  brainchild behind “Cannabinoid Medical Clinic”, a superchain series of clinics that specializes in the niche of assessing the prescription of cannabinoid-based medicinal treatments to patients that are referred only, no exceptions. There are currently ten clinics at the moment operating across Canada, from bustling Toronto to windy Edmonton. The expansion is on, as Canabo Medical recently went public on the Toronto Stock Exchange (Venture). As far as Dr. Schecter is concerned, it wouldn’t be a far fetched thing to say if I called him the encyclopedia of medicinal marijuana.

    He first learned about cannabinoid medicine at the University of Montreal. He trained shoulder-to-shoulder with some of the brightest academias in the field of medicinal marijuana in Canada. Therefore, I also come to the conclusion, that it would be just right to call him an expert in this field.

    It’s not just about his background, but the positive results he’s clocking in for Cannabinoid Medical Clinics.  As for business? It’s booming. Dr. Danial highlighted in an interview to lift that he on average sees 6 new patients and 18 follow ups on a regular day. Take into account the consultation fees for all 10 operating clinics and incoming clinics nationwide across Canada, with the patient number and follow up in mind, things are looking good for senior management. That very senior management is set to exploit an untapped niche in Canada. The reason why I say untapped is based on real life lessons. We have a lot of clinics here in Toronto. Approximately 90%, or probably even more, are your typical back-door, approve everyone type alternative therapy advisers or whatever. They’re normally given a mandate to approve all. I know because I have tested a lot of dispensaries and clinics alike here in Toronto. Canabo truly sets itself apart by underlining itself as a legitimate player due to two primary factors: the fact that appointments are reference based only through a family doctor or practicioner (unlike most others here in Toronto where only profits matter) and the simple fact that it doesn’t sell the product. These two ingredients indicate a priority given to what the boys on the block like to call, ‘Big Data.’

    Big Data, eh? Some people are discrediting Dr. Schecter’s vast experience by pinning the data collection and compliance side of what Canabo is doing for the cannabis industry as something of a lie. Chris Parry called this out for what it is on Twitter, as something of a deliberate wrongdoing. I agree with him because Dr. Schecter and his team aren’t a bunch of marketers trying to sell early data and make quick profits as some would like to suggest is with the case is with most venture listed firms, though that is nothing but bullshit. They have set the bar high to focus and carve a big share in the data collection side of cannabis.

    All you need to do to be convinced is simply understand the process of how the clinics operate. Remember, I have always preached simplicity when it comes to investment thesis and market psychology, and perhaps you should too. All it really takes is just a matter if due diligence. Dr. Schecter, in his interview to lift, stated, “I spend a minimum of 50 minutes with each new patient to understand what their past medical history is, what their main complaints and impairments are, what they have tried and failed in the past and understand what they are hoping to achieve by coming to the clinic.” Now that you’re a bit familiarized with the process, then you can easily answer for yourself whether Canabo is big data or not.

    This data can be utilized by Canabo itself through very simple, yet lucrative solutions to important strain related questions. Leafly is a great startup, don’t get me wrong, but Canabo will have the sort of demographics, results, and information that the government and licensed producers probably can’t wait to get their hands on. Oh, I totally forgot. This data will also have answers to question Leafy won’t have, like which strain is best for which age group. That’s fucking cool.

    Of course, I haven’t really gone over all of what Canabo offers because Chris Parry has already done that job. 

    This is a link to Chris Parry’s article on CMM.VN (listed on the TSXV): http://www.equity.guru/2016/11/28/canabo-medical-v-cmm-a-cannabis-business-model-thats-already-far-bigger-than-you-know/

    Click Here For Full Corporate Information

     

    ~ written by Hamzah Khan 


    Pursuant to an agreement between MAPH and Canabo Medical Corp (CMM), we were hired for a period beginning November 14 2016 and ending December 14, 2016 to publicly disseminate information about (CMM) including on the Website and other media including Facebook and Twitter. We are being paid $15,000 (CASH) for or were paid “0” shares of restricted common shares. We may buy or sell additional shares of (CMM)in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please refer to full disclaimer for more information

    0 749

    Could having a recreational marijuana program hurt the medical marijuana community? An analyst from GreenWave Advisors is under the impression that legalized retail marijuana will disturb the emerging medical sector. For the states that have legalized recreational marijuana, the number of medical marijuana patients has dropped. It was long speculated that many individuals who just wanted to smoke pot stated they have a medical condition such as chronic pain in order to legally buy and use marijuana.

    Having some form of Chronic discomfort or pain is generally the most common qualifying condition and this is the group that drops in patient counts when retail marijuana becomes available The analysts’ report highlights that the amount of patient decelerated in Colorado, Oregon and Washington D.C. Washington state does not count patients and Alaska patients can grow their medicine at home making it more difficult to keep count.

    GreenWave wrote, “Though Arizona permits only medicinal use, new cardholder applications were down sharply in May, perhaps in anticipation of a favorable election outcome for recreational use.” Another data point that supports the idea that some chronic pain sufferers are really retail customers is that medical marijuana spending patterns follow retail purchase habits.

    Sales among recreational marijuana users spike during the holiday season in December, summer and the classic 420 celebrations. This isn’t to imply that all patients who suffer from pain are really retail customers, although it does suggest that the medical market could be smaller than previously thought.

    The GreenWave report also indicates that as long as the DEA leaves marijuana as a schedule 1 drug, doctors will continue to stay away from recommending the drug, further limiting the medical market. GreenWave anticipates that as recreational marijuana markets begin to shrink the medical markets, various states will start to merge the regulatory oversight of both the recreational and medical marijuana markets.

    The report stated, “Redundancy in oversight and enforcement mechanisms will be recognized as costly confusing.” The report is careful to highlight that it isn’t predicting the downfall of the medical marijuana market. The group believes that as new, and more targeted drugs become available and doctors become more involved, the medical sector will recalibrate.

    0 2166

    Ubiquitech Software Announces Name Change to “HempLife Today” Plus Releases Overview of Exciting Plans to Increase Revenues and Continue Company Growth

    DENVER, CO–(Marketwired – Sep 20, 2016) – Ubiquitech Software Corp. ( OTC PINK : UBQU ), CEO and the management of (UBQU) want all shareholders, and the general public, to have an update and overview on the exciting plans the company is implementing in order to continue the upward growth of revenues and the expansion of the CannazALL™ CBD brand.

    The company currently has plans for the following over the next 30 – 120 days, and into 2017, and will be very active in keeping shareholders and the general public updated on a weekly basis…

    Official Name and symbol change to HempLife Today™: Pending the legal requirement filings the company will be known as HempLife Today™, with new symbol (To replace UBQU), also pending. The company believes that the already extensive reach of the HempLife Today™ name, the millions spent on branding, and the ability to leverage this brand into a worldwide powerhouse is the best choice to expand the CannazALL™ CBD product line to a larger market share, and offers greater flexibility and profit potential as the Hemp industry continues to grow.

    New HempLife Today™ logo: Update and freshen the HempLife Today™ logo to add a stronger look to our brand.

    New products: The Company has plans to announce 2-4 new CBD products in 2016.

    New and improved packaging: To increase customer satisfaction, increase public awareness, and also allow for greater retail sales opportunities.

    New proprietary CBD blend: The company is currently developing a new proprietary blend of additional hemp plant products to its CannazALL™ CBD formulas. Making CannazALL™ even more a one-of-a-kind and unique CBD health product, that can only be found in the CannazALL™ brand.

    Introduction of Direct Mail to advertising campaigns. The company is introducing direct mail campaigns to its buyers and subscriber lists, and will be expanding this advertising campaign to larger databases of potential new customers

    CBD GelCap Free Sample: As announced on 9.16.2016…The Company will be BETA testing this offer in October with plans to roll out in November and December. Current data show the Company could add over 50,000- 100,000 new customers annually through this marketing platform.

    Additional Affiliate companies: The Company is currently working with “Content Specific” Sites that can act as Affiliate sellers of CannazALL™ CBD products. Company announced PotGuide.com and ColoradoPotGuide.com were added to its Affiliates earlier this month.

    New CannazALL™ YouTube channel: The Company plans to create a new YouTube channel that will offer instructions and details on CannazALL™ products, dosing, and general information.

    New company, product, and investor video presentations: To be added to the HempLife Today™ Websites and landing pages.

    Improved Delivery: It is the Company goal to ship same day on orders placed before 9Am (MT), and next day on orders placed after 9AM. Company data show that fast shipping results in more frequent, and larger, repeat orders.

    International sales: Expanded delivery into other CBD friendly countries (To be announced in future Press Releases)

    “Going into our third year we are solidifying everything necessary to succeed and be the leader” Said Tim Zorn of HempLife Today™ “Our products are the best they can be, the demand for our products is growing, and our name, brand, and production and delivery systems, are all in place. We are ready to spread the HempLife Today name, and the Cannazall CBD brand, to a bigger and bigger audience”

    “If people think that 2016 has been good so far, just watch what we achieve moving forward” James Ballas of HempLife Today™ “With our new name and symbol change we are ready to expand and grow this company faster than ever before. We feel like a sprinter that’s about to reach full speed, and once we do, there will be no catching us”

    The company is aware that shareholders, and the public, are eager to learn about, and to share, all of the new and exciting plans the company is implementing. Because of this the Company will keep shareholders completely informed on a weekly, and sometimes daily, basis to show the progress of the stated goals in this press release.

    About Ubiquitech (HempLife Today™)
    Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, Direct Response (DRTV) Television, Radio, and traditional marketing, to drive traffic to the new and emerging multi-billion dollar industries like its subsidiary HempLifeToday.com™

    HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, all offered @ www.HempLifeToday.com

    This press release contains forward-looking statements. Words such as “expects”, “intends”, “believes”, and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the date of this release.

    0 882

    Washington’s plan for a centrally prearranged market in pot creates a breeding ground for a completely unplanned and illegal market of marijuana. Washington voters legalized recreational marijuana in 2012 and the first retail store opened in 2014. So why are authorities are moving to close pot shops across the state in just a few weeks

    Tacoma ranks among the municipalities where new licensing regulations will have a major impact on the marijuana market, potentially inconveniencing consumers and creating a huge opening for those willing to work outside official channels.

    “Last August, there were close to 70 unlicensed operators in Tacoma,” The News Tribune said last week. But a law that was passed in 2015 merged the medical and recreational markets and required all vendors to be licensed. “Tacoma is limited by the state to 16 retail licenses, and a recent city ordinance requires every retail operator also to get a medical endorsement to provide for those with medicinal needs.”

    “We illustrate the methods and tools for two particular target numbers
    But black market dealers don’t appear just because marijuana—or anything else—is technically outlawed; they arise when restrictions drive prices up, restrict availability, or both, and leave an opening for vendors willing to flout the law to satisfy demand. Cigarettes are legal, but they had such a high tax and restricted as to invite illegal dealers to enter the market and make a buck. Even before the latest change, Washington’s underground economy in marijuana was thriving despite its nominally legal status.”

    BOTEC’s reports for the state fully acknowledge the existence of the marijuana black market. In fact, “Due to the considerable amount of uncertainty in the estimation process, as well as the rapidly changing nature of cannabis markets in Washington at present, it is valuable to reference feasible ranges rather than a single point estimate.”

    That is, the whole marijuana market is too dynamic and in flux to get a firm handle on its size.

    0 562

    Since the last federal election in 2012, the United States has seen a huge change in voter attitude for both recreational and medical cannabis. At the moment, there are four states, and the United States’s capital, D.C., that have voted to legalize the sale of recreational marijuana.

    Most presidential candidates have seen these states as test subjects for possible legalization, and while some candidates themselves do not support ending cannabis prohibition, they have admitted that they may not share the same opinion as the majority of the population. With this mixture, they are choosing to let the voters speak. As more and more people begin to ask for cannabis reform, the issue has received a lot of popularity among the candidates’ platforms. The biggest change seen has been from the Republican party, which has always been anti-marijuana.

    In the same way that he seems about other issues, Donald Trump’s position on pot is dubious to completely understand. He says that America has lost the War on Drugs, however, has conflicting perspectives on whether cannabis ought to be legalized. In the 1990s, he was willing to legalize cannabis. However, he has moved into a more hardline ideology against recreational cannabis while supporting it for medicinal purposes. Since 2015, he has once more loosened his position, saying that he is going to respect the states’ choices.

    While constantly changing positions have ended up being one of Trump’s trademarks, his position on weed is in-accordance with the rest of the Grand Old Party. Ted Cruz has turned to be personally against the utilization of cannabis yet has seen states such as Colorado and Washington as “laboratories of democracy.” He has expressed that on the off chance that he was chosen, he wouldn’t change current laws and would permit every state to decide their own arrangement going ahead.

    0 599

    The citizens of California are going to decide in November if they would like to legalize recreational cannabis. California is the country’s most populated state. California’s secretary of state said on Tuesday that the bill had obtained enough signatures to be put on the ballot. In addition to that, according to a news article, the supporters of the ballot had raised $3.53 million. That’s almost 31 times more than what opponents had generated. The measure would allow adults 21 or older to have, transport, and buy up to an ounce of cannabis. They would also be able to cultivate up to six plants for recreational use.

    “Today marks a fresh start for California, as we prepare to replace the costly, harmful and ineffective system of prohibition with a safe, legal and responsible adult-use marijuana system that gets it right and completely pays for itself,” Jason Kinney, spokesman for the Adult Use of Marijuana Act, reports.

    If the measure is approved by the people of California, the reduction in costs to local and state governments for enforcing cannabis-related laws could go past $100 million per year, according to the statement from the secretary of state. At the same time, annual state and local tax revenues from a legal cannabis industry could go up to over $1 billion. This would “be required to be spent for specific purposes such as substance use disorder education, prevention, and treatment.”

    Here are the supporters of the measure: the California Democratic Party, California Lt. Gov. Gavin Newsom, the California NAACP and the ACLU of California. In addition, former Facebook President Sean Parker has also given a good amount of money. In 2010, a similar bill was rejected, but proponents “say the new measure has a better chance because it adds more regulation at the state level rather than letting locals dictate what happens, and comes after the state has approved a regulatory system for medical marijuana growing, transportation and sales.”

    0 869

    Sponsors of a measure with the goal of legalizing cannabis in North Dakota did not receive a sufficient amount of signatures by the July 11th deadline to make it onto the ballot on November 8th, a sponsor said. The speakers needed to collect at least 13,452 signatures to the secretary of state’s office.

    “Sounds like we just missed the mark. We had about 80 percent of the signatures we needed but weren’t able to get them all,” Tony Mangnall of Fargo, a member of the sponsoring committee and chairman of the North Dakota Libertarian Party, which endorsed the proposed initiative, stated.

    Committee chairman Eric Olson of Fargo was not able to provide a comment. The proposed bill would have made it legal for anyone aged 21 or older to cultivate, have, use, and distribute cannabis without a license. Cannabis and cannabis paraphernalia would not have been able to be taxed by more than twenty percent. Mangnall stated that sponsors are going to collect signatures again another time to make it onto the ballot in 2018. They state that the reason they weren’t able to gather enough signatures is that they needed to resubmit the measure after their initial one’s language had errors, taking months off of their timeframe.

    “Probably next time around we’ll have all the signatures we need,” Mangnall added.

    At the same time, sponsors of a proposed bill to legalize medical cannabis planned to give the signatures to Secretary of State Al Jaeger at two p.m. Monday, July 11. They announced last week that they had approximately 15,500 signatures. Those signatures need to be checked for legitimacy, but if the right amount of signatures passed, the Compassionate Care Act would allow for the possession of up to three ounces of medical cannabis for treatment of more than twelve debilitating medical conditions. Here are examples of just a few: cancer, epilepsy, AIDS, and glaucoma.

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements